Examining the Effect of Burosumab on Muscle Function
Conditions
Diseases of the Musculoskeletal System
Phase COVID-NA
Volunteers
Health Professionals
What is the purpose of this trial?
Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The investigators wish to test this hypothesis directly by measuring muscle energy when patients begin treatment with Crysvita® for the first time.
- Ages18 years - 65 years
- GenderBoth
- Trial withYale University School of Medicine
- Start Date02/13/2020
- End Date09/30/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated05/18/2022
- Study HIC#2000026400